Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

Sarah A. Taylor, Dorothy J. Giroux, Kurt Jaeckle, Timothy J. Panella, Shaker R. Dakhil, S. Clifford Schold

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

Original languageEnglish (US)
Pages (from-to)331-332
Number of pages2
JournalInvestigational New Drugs
Volume16
Issue number4
DOIs
StatePublished - Dec 1 1998

Fingerprint

didemnins
Central Nervous System Neoplasms
Lethargy
Nausea
Vomiting
Neoplasms
Central Nervous System

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Taylor, S. A., Giroux, D. J., Jaeckle, K., Panella, T. J., Dakhil, S. R., & Schold, S. C. (1998). Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study. Investigational New Drugs, 16(4), 331-332. https://doi.org/10.1023/A:1006273214056
Taylor, Sarah A. ; Giroux, Dorothy J. ; Jaeckle, Kurt ; Panella, Timothy J. ; Dakhil, Shaker R. ; Schold, S. Clifford. / Phase II study of Didemnin B in central nervous system tumors : A Southwest Oncology Group study. In: Investigational New Drugs. 1998 ; Vol. 16, No. 4. pp. 331-332.
@article{c979d9a0aff24fe99ea5ee99afbc5c05,
title = "Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study",
abstract = "Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9{\%}, 95{\%} confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.",
author = "Taylor, {Sarah A.} and Giroux, {Dorothy J.} and Kurt Jaeckle and Panella, {Timothy J.} and Dakhil, {Shaker R.} and Schold, {S. Clifford}",
year = "1998",
month = "12",
day = "1",
doi = "10.1023/A:1006273214056",
language = "English (US)",
volume = "16",
pages = "331--332",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

Taylor, SA, Giroux, DJ, Jaeckle, K, Panella, TJ, Dakhil, SR & Schold, SC 1998, 'Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study', Investigational New Drugs, vol. 16, no. 4, pp. 331-332. https://doi.org/10.1023/A:1006273214056

Phase II study of Didemnin B in central nervous system tumors : A Southwest Oncology Group study. / Taylor, Sarah A.; Giroux, Dorothy J.; Jaeckle, Kurt; Panella, Timothy J.; Dakhil, Shaker R.; Schold, S. Clifford.

In: Investigational New Drugs, Vol. 16, No. 4, 01.12.1998, p. 331-332.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II study of Didemnin B in central nervous system tumors

T2 - A Southwest Oncology Group study

AU - Taylor, Sarah A.

AU - Giroux, Dorothy J.

AU - Jaeckle, Kurt

AU - Panella, Timothy J.

AU - Dakhil, Shaker R.

AU - Schold, S. Clifford

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

AB - Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0032457858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032457858&partnerID=8YFLogxK

U2 - 10.1023/A:1006273214056

DO - 10.1023/A:1006273214056

M3 - Article

C2 - 10426666

AN - SCOPUS:0032457858

VL - 16

SP - 331

EP - 332

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -